Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
Summary
The goal of this Phase I/II observational and interventional platform study is to evaluate the safety and efficacy of multiple types of innovative anti-tumor drugs and new technologies in patients with rare solid tumors. The study utilizes multi-dimensional precision screening (including WES, RNAseq, mIHC, and quantitative proteomics) to match patients with specific sub-protocols. Key questions it aims to answer: Assess the safety of innovative therapies in rare tumor populations. Evaluate the objective response rate (ORR) and other efficacy metrics. Explore biomarkers related to therapeutic efficacy. Participants: Patients with metastatic or advanced rare solid tumors who have failed standard therapy or have no standard treatment options.
Timeline
- Start
- 2026-01-01
- Primary completion
- 2029-01-31
- Completion
- 2031-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BL-B01D1 | Unknown | — | — |
| Subject | BMD006 | Messenger RNA (mRNA) | — | Inhaled |
| Subject | CE120 | Other / unclassified | — | Other |
| Subject | CREPT-618 | Oligonucleotide (other) | — | — |
| Subject | CVL006 | Monoclonal antibody | — | — |
| Subject | GV20-0251 | Monoclonal antibody | — | — |
| Subject | IBI363 | Protein / enzyme biologic | — | — |
| Subject | IDOV-SAFE | Unknown | — | — |
| Subject | KXV01 | Cell therapy | — | Intravenous |
| Subject | LYC001 | Protein / enzyme biologic | — | — |
| Subject | MT027 | Cell therapy | — | Other |
| Subject | Meta10-TIL | Cell therapy | — | Intravenous |
| Subject | NK510 | Cell therapy | — | — |
| Subject | PRG2505 | Cell therapy | — | — |
| Subject | QH101 | Cell therapy | — | Intrathecal |
| Subject | TAEST1901 | Cell therapy | — | Intravenous |
| Subject | TC-N201 | Cell therapy | — | — |
| Subject | VSV | Unknown | — | — |
| Subject | YL201 | Other / unclassified | — | — |
| Subject | YSCH-01 | Unknown | — | — |